Published in Neurobiol Aging on October 09, 2013
The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimers Dement (2015) 1.66
Alzheimer's disease genetics: from the bench to the clinic. Neuron (2014) 1.65
Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med (2016) 1.44
Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet (2014) 1.36
TREM2 is associated with increased risk for Alzheimer's disease in African Americans. Mol Neurodegener (2015) 1.05
Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J Biol Chem (2015) 1.04
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol (2016) 1.03
The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. J Biol Chem (2015) 1.03
Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations. Hum Mol Genet (2014) 1.02
Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease. J Neurosci (2015) 0.99
TREM2 Protein Expression Changes Correlate with Alzheimer's Disease Neurodegenerative Pathologies in Post-Mortem Temporal Cortices. Brain Pathol (2014) 0.98
sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med (2016) 0.97
TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci (2016) 0.97
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener (2016) 0.96
DAP12 Stabilizes the C-terminal Fragment of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) and Protects against LPS-induced Pro-inflammatory Response. J Biol Chem (2015) 0.95
TREM2 in CNS homeostasis and neurodegenerative disease. Mol Neurodegener (2015) 0.89
R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimers Dement (2014) 0.89
R47H Variant of TREM2 Associated With Alzheimer Disease in a Large Late-Onset Family: Clinical, Genetic, and Neuropathological Study. JAMA Neurol (2015) 0.88
Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. Front Aging Neurosci (2015) 0.87
More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. Neurobiol Aging (2015) 0.85
TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med (2016) 0.84
The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases. J Biol Chem (2015) 0.82
The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. Alzheimers Dement (2014) 0.82
The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease. Neurobiol Aging (2015) 0.82
The Role of TREM2 in Alzheimer's Disease and Other Neurological Disorders. J Alzheimers Dis Parkinsonism (2014) 0.81
Identification of rare variants in Alzheimer's disease. Front Genet (2014) 0.80
Additional mechanisms conferring genetic susceptibility to Alzheimer's disease. Front Cell Neurosci (2015) 0.79
Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities. Expert Rev Mol Diagn (2015) 0.79
TREM2 variants and risk of Alzheimer's disease: a meta-analysis. Neurol Sci (2015) 0.78
Preparation, crystallization, and preliminary crystallographic analysis of wild-type and mutant human TREM-2 ectodomains linked to neurodegenerative and inflammatory diseases. Protein Expr Purif (2014) 0.77
Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci (2014) 0.76
Modeling Alzheimer's Disease with Induced Pluripotent Stem Cells: Current Challenges and Future Concerns. Stem Cells Int (2016) 0.75
CLEC4C p.K210del variant causes impaired cell surface transport in plasmacytoid dendritic cells of amyotrophic lateral sclerosis. Oncotarget (2016) 0.75
TREM2-ligand interactions in health and disease. J Mol Biol (2017) 0.75
Novel susceptibility loci for Alzheimer's disease. Future Neurol (2015) 0.75
Association study of TREM2 polymorphism rs75932628 with leucoaraiosis or Parkinson's disease in the Han Chinese population. BMJ Open (2016) 0.75
Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer's Disease. Biomed Res Int (2017) 0.75
The Alzheimer's Disease-Associated R47H Variant of TREM2 Has an Altered Glycosylation Pattern and Protein Stability. Front Neurosci (2017) 0.75
An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol Med (2017) 0.75
TREM2 in Neurodegenerative Diseases. Mol Neurodegener (2017) 0.75
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature (2006) 9.31
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
novoSNP, a novel computational tool for sequence variation discovery. Genome Res (2005) 7.42
The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science (2013) 6.34
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
On the use of scaling and clustering in the study of semantic deficits. Neuropsychology (2003) 5.38
A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol (2011) 5.01
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA (2006) 4.26
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol (2011) 3.69
TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A (2010) 3.39
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. Am J Hum Genet (2003) 3.02
Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat Genet (2004) 2.86
Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol (2009) 2.83
ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol (2007) 2.80
Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet (2007) 2.63
Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Hum Genet (2011) 2.63
Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet (2008) 2.45
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat (2010) 2.29
Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat (2006) 2.29
hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol (2013) 2.27
APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain (2006) 2.23
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat (2012) 2.17
A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann Neurol (2004) 2.09
High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet (2005) 2.08
alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol (2004) 1.97
Genetic insights in Alzheimer's disease. Lancet Neurol (2013) 1.96